Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[News in HIV infection, long-acting injectable treatments].
Nawej Tshikung O, Segeral O, Cavassini M, Calmy A. Nawej Tshikung O, et al. Among authors: calmy a. Rev Med Suisse. 2023 Feb 1;19(812):243-249. doi: 10.53738/REVMED.2023.19.812.243. Rev Med Suisse. 2023. PMID: 36723657 Review. French.
Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach.
Labarile M, Loosli T, Zeeb M, Kusejko K, Huber M, Hirsch HH, Perreau M, Ramette A, Yerly S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux C, Günthard HF, Pasin C, Kouyos RD; Swiss HIV Cohort Study. Labarile M, et al. Among authors: calmy a. J Infect Dis. 2023 Feb 14;227(4):554-564. doi: 10.1093/infdis/jiac457. J Infect Dis. 2023. PMID: 36433831 Free article.
Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study.
Bosetti D, Mugglin C, Calmy A, Cavassini M, Stöckle M, Braun D, Notter J, Haerry D, Hampel B, Kovari H, Bernasconi E, Wandeler G, Rauch A; Swiss HIV Cohort Study. Bosetti D, et al. Among authors: calmy a. Open Forum Infect Dis. 2022 Nov 16;9(12):ofac592. doi: 10.1093/ofid/ofac592. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36504700 Free PMC article.
[Monkeypox: a new emerging infectious threat?].
Segeral O, Musumeci S, Kaiser L, Calmy A. Segeral O, et al. Among authors: calmy a. Rev Med Suisse. 2023 Apr 12;19(822):702-707. doi: 10.53738/REVMED.2023.19.822.702. Rev Med Suisse. 2023. PMID: 37057850 French.
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.
Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O; Swiss HIV Cohort Study. Franceschi S, et al. Among authors: calmy a. Br J Cancer. 2010 Jul 27;103(3):416-22. doi: 10.1038/sj.bjc.6605756. Epub 2010 Jun 29. Br J Cancer. 2010. PMID: 20588274 Free PMC article.
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.
Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, Jensen BO, Vandekerckhove L, Jurado M, Raj K, Schulze Zur Wiesch J, Bailén R, Eberhard JM, Nabergoj M, Hütter G, Saldaña-Moreno R, Oldford S, Barrett L, Ramirez MLM, Garba S, Gupta RK, Revollo B, Ferra-Coll C, Kuball J, Alter G, Sáez-Cirión A, Diez-Martin JL, Duke ER, Schiffer JT, Wensing A, Martinez-Picado J; IciStem Consortium. Salgado M, et al. Lancet HIV. 2024 Jun;11(6):e389-e405. doi: 10.1016/S2352-3018(24)00090-0. Lancet HIV. 2024. PMID: 38816141
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trial.
Marinosci A, Sculier D, Wandeler G, Yerly S, Stoeckle M, Bernasconi E, Braun DL, Vernazza P, Cavassini M, Buzzi M, Metzner KJ, Decosterd L, Günthard HF, Schmid P, Limacher A, Branca M, Calmy A. Marinosci A, et al. Among authors: calmy a. Swiss Med Wkly. 2024 Apr 15;154:3762. doi: 10.57187/s.3762. Swiss Med Wkly. 2024. PMID: 38754068 Free article. Clinical Trial.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM, Rizzardini G, Orrell C, Afani A, Calmy A, Oka S, Hinestrosa F, Kumar P, Tebas P, Walmsley S, Grandhi A, Klopfer S, Gendrano I, Eves K, Correll TA, Fox MC, Kim J. Molina JM, et al. Among authors: calmy a. Lancet HIV. 2024 Jun;11(6):e369-e379. doi: 10.1016/S2352-3018(24)00031-6. Epub 2024 May 8. Lancet HIV. 2024. PMID: 38734015 Clinical Trial.
647 results